CN116920021A

CN116920021A - Traditional Chinese medicine composition for treating novel coronavirus infection, clinical preparation and preparation method

Info

Publication number: CN116920021A
Application number: CN202211629606.2A
Authority: CN
Inventors: 薛毅; 张亚京
Original assignee: Hebei Kangnada Biotechnology Co ltd
Current assignee: Hebei Kangnada Biotechnology Co ltd
Priority date: 2022-12-16
Filing date: 2022-12-16
Publication date: 2023-10-24

Abstract

The invention relates to a traditional Chinese medicine composition for treating novel coronavirus infection, which comprises the following raw materials in parts by weight: radix Morindae officinalis: 20-30 parts of a lubricant; 20-30 parts of chrysanthemum; 20-30 parts of bupleurum. The invention can effectively inhibit the replication of the novel coronavirus, promote the rapid negative transfer of the novel coronavirus infection, has small side effect and low cost, and can be widely popularized and used.

Description

Traditional Chinese medicine composition for treating novel coronavirus infection, clinical preparation and preparation method

Technical Field

The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating novel coronavirus infection, a clinical preparation and a preparation method thereof.

Background

The novel coronavirus SARS-CoV-2 is the 7 th currently known coronavirus which can infect human and has many variations. It can infect cells through binding of spike glycoprotein (spike, S protein) to respiratory angiotensin converting enzyme (ACE 2). Common signs of people infected with novel coronaviruses are respiratory symptoms, fever, cough, shortness of breath, dyspnea and the like. In more severe cases, the infection can lead to pneumonia, severe acute respiratory syndrome, renal failure, and even death.

There is no specific treatment for the disease caused by the novel coronavirus. At present, antiviral treatment is mainly used and symptomatic treatment is assisted, however, the existing antiviral drugs are mainly drugs for influenza A or influenza B, have relatively poor pertinence to novel coronaviruses, and are researched and considered to be the Redexi having remarkable curative effect to the novel coronaviruses, and belong to western medicine category, have large side effects, are successfully developed by foreign companies, are expensive, exceed the bearing range of common families and are not suitable for conventional treatment of the common families; therefore, it is important to develop a traditional Chinese medicine composition, a clinical preparation and a preparation method which have low side effects and low cost and can be widely popularized and used, inhibit the replication of novel coronaviruses and promote the rapid transfer of the yin of the novel coronavirus infection.

Disclosure of Invention

The invention aims to overcome the defects in the prior art, and provides a traditional Chinese medicine composition for treating novel coronavirus infection, a clinical preparation and a preparation method thereof, which can effectively inhibit replication of the novel coronavirus, promote rapid negative turning of the novel coronavirus infection, have small side effect and low cost, and can be widely popularized and used.

In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:

the technical scheme is as follows:

a traditional Chinese medicine composition for treating novel coronavirus infection comprises the following raw materials in parts by weight:

radix Morindae officinalis: 20-30 parts of a lubricant; 20-30 parts of chrysanthemum; 20-30 parts of bupleurum.

As a preferred technical scheme, the traditional Chinese medicine composition for treating the novel coronavirus infection comprises the following raw materials in parts by weight: radix Morindae officinalis: 25 parts; 25 parts of chrysanthemum; 25 parts of bupleurum.

As a preferred technical scheme, a traditional Chinese medicine composition for treating novel coronavirus infection further comprises pharmaceutically acceptable auxiliary materials, such as: fillers, disintegrants, lubricants, suspending agents, binders, preservatives, matrices, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, and the like; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, crosslinked sodium carboxymethyl cellulose, and the like; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the binder includes starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.; the preservative comprises: nipagin, benzoic acid, sodium benzoate, sorbic acid and salts thereof, benzalkonium bromide, chlorhexidine acetate, eucalyptus oil and the like; the matrix comprises: PEG6000, PEG4000, insect wax, and the like. In order to realize the traditional Chinese medicine pharmacy of the dosage forms, other pharmaceutically acceptable auxiliary materials are required to be added in the preparation of the dosage forms.

The second technical scheme is as follows:

a clinical preparation comprising the traditional Chinese medicine composition for treating novel coronavirus infection.

As a preferred technical scheme, the clinical preparation is an oral preparation; the oral preparation is selected from decoction, powder, capsule, tablet, mixture, syrup, oral paste, pill or oral liquid.

The technical scheme is as follows:

the preparation method of the clinical preparation comprises the following steps:

step 1, weighing the raw materials in parts by weight, and crushing to obtain raw material powder;

step 2, adding water (distilled water) into the raw material powder, decocting for 2-3 times under the stirring condition of 90-100 ℃, filtering, combining the filtrates, and concentrating under reduced pressure to obtain paste;

and 3, freeze-drying the paste to obtain dry paste powder.

In the step 2, after the filtrates are combined, the filtrate is centrifuged for 5-15min at a rotation speed of 2500-3500r/min at low temperature, and then the supernatant is dried under reduced pressure.

As a preferable technical scheme, the low temperature is 0-5 ℃, the centrifugal speed is 3000r/min, and the centrifugal time is 10min.

As a preferable technical scheme, the mass-volume ratio of the raw material powder to water is 25g to 1L based on dry weight during the decoction;

the filtering adopts a 80-120 mesh sieve;

the temperature of the reduced pressure concentration is 50-55 ℃.

As a preferred technical scheme, the filtration adopts a 100-mesh sieve.

As a preferable technical scheme, the method further comprises the following steps of 4 and granulating:

mixing the dry paste powder and starch at a mass ratio of 1:0.5-1.5, adding 80-90% ethanol solution to obtain soft material, granulating with 16-20 mesh sieve, oven drying at 60-65deg.C, and sieving with 14-18 mesh sieve to obtain granule.

As a preferable technical scheme, granulating by adopting an 18-mesh sieve; and (3) finishing the granules by adopting a 16-mesh screen.

As a preferable technical scheme, the granules prepared in the step 4 are encapsulated to prepare a capsule preparation;

or tabletting the granules prepared in the step 4 to obtain tablets.

The technical scheme is as follows:

the application of the traditional Chinese medicine composition for treating the novel coronavirus infection or the clinical preparation prepared by the preparation method in preparing the medicine for treating the novel coronavirus infection.

Compared with the prior art, the invention has the beneficial effects that:

the morinda officinalis root with antiviral effect is used as a main medicine, the novel coronavirus is promoted to quickly turn negative, the morinda officinalis root has sweet and pungent taste and slightly warm nature, and has the effects of tonifying kidney yang, strengthening tendons and bones and dispelling wind-damp, 100g of morinda officinalis root bark contains 385 mug of zinc, and zinc element zinc can act on ACE2, spike protein and RNA, so that the morinda officinalis root has the effect of inactivating the novel coronavirus, and in addition, the morinda officinalis root also contains methyl naphthoate which belongs to anthraquinone compounds and has good anti-inflammatory and antibacterial effects.

The chrysanthemum and the bupleurum with the effects of clearing heat and detoxicating are taken as auxiliary medicines, wherein the chrysanthemum has the effects of dispelling wind and clearing heat, calming liver and improving eyesight, and clearing heat and detoxicating. Is used for treating wind-heat common cold, headache, dizziness, conjunctival congestion, swelling and pain, dim eyesight, sore, carbuncle, and toxic swelling, and bupleuri radix has effects of dispelling pathogenic wind, clearing heat, suppressing hyperactive liver, improving eyesight, removing toxic substance, and relieving swelling.

The traditional Chinese medicine preparation has the advantages of being used together, supplementing each other in effect, acting together, being capable of effectively inhibiting the replication of novel coronaviruses, promoting the rapid negative turning of the novel coronaviruses, being small in side effect and low in cost, and being capable of being widely popularized and used.

Drawings

FIG. 1 is a graph of cell viability of Rede Siwei at various concentrations;

FIG. 2 is a graph showing the relationship between the cell viability of KND-COVID-III at various concentrations;

FIG. 3 is a graph showing the relationship between the viral inhibition of Rede Siwei at various concentrations;

FIG. 4 is a graph showing the relationship between the virus inhibition rate of KND-COVID-III at different concentrations;

Detailed Description

The present invention will be described in further detail with reference to examples.

Example 1:

a traditional Chinese medicine composition for treating novel coronavirus infection comprises the following raw materials in parts by weight: radix Morindae officinalis: 25 parts; 25 parts of chrysanthemum; 25 parts of bupleurum.

A dry paste powder prepared by taking the traditional Chinese medicine composition as a raw material, and a preparation method thereof comprises the following steps:

step 2, adding distilled water into the raw material powder, decocting for 2 times under the stirring condition of 100 ℃, filtering by adopting a 100-mesh stainless steel standard inspection sieve, merging filtrate, centrifuging the filtrate at a low temperature of 0 ℃ at a rotating speed of 3000r/min for 10min, collecting supernatant, and concentrating the supernatant at a temperature of 50-55 ℃ under reduced pressure to obtain paste;

in each decoction, the weight and volume ratio of the raw material powder to distilled water is 25g: adding distilled water into 1L, and decocting for 1 hr;

and 3, freeze-drying the paste to obtain dry paste powder.

Example 2

A Chinese medicinal composition for treating novel coronavirus infection comprises the following raw materials by weight: radix Morindae officinalis: 30g; 25g of chrysanthemum; 30g of bupleurum.

The preparation method of the granule prepared by taking the traditional Chinese medicine composition as a raw material comprises the following steps:

in each decoction, the weight and volume ratio of the raw material powder to distilled water is 25g: adding distilled water into 1L, wherein the time of each decoction is ih;

the time of each decoction is ih;

step 3, freeze-drying the paste to obtain dry paste powder;

step 4, granulating: the mass ratio of the dry paste powder to the starch is 4:3, uniformly mixing the dry paste powder with starch, adding an ethanol solution with the mass concentration of 85% to prepare a soft material, granulating by a 18-mesh sieve, drying at 60-65 ℃, and finishing granules by a 16-mesh sieve to obtain granules.

Example 3

A Chinese medicinal composition for treating novel coronavirus infection comprises the following raw materials by weight: radix Morindae officinalis: 20g; 30g of chrysanthemum; 25g of bupleurum.

A capsule preparation prepared by taking the traditional Chinese medicine composition as a raw material comprises the following steps:

adding distilled water according to the mass-volume ratio of the raw material powder to the distilled water of 25g to 1L in terms of dry weight when each time of decoction, wherein the time of each time of decoction is 1h;

the time of each decoction is 1h;

step 3, freeze-drying the paste to obtain dry paste powder;

step 4, granulating: mixing the dry paste powder and starch according to the mass ratio of the dry paste powder to the starch of 4:3, adding an ethanol solution with the mass concentration of 85% to prepare a soft material, granulating by a 18-mesh sieve, drying at 60-65 ℃, and finishing granules by a 16-mesh sieve to obtain granules;

and 5, subpackaging the particles into capsule shells to prepare the capsule preparation.

Example 4

A Chinese medicinal composition for treating novel coronavirus infection comprises the following raw materials by weight: radix Morindae officinalis: 26g; 25g of chrysanthemum; 20g of bupleurum.

the time of each decoction is 1h;

step 3, freeze-drying the paste to obtain dry paste powder;

and 5, tabletting the granules to obtain a tablet preparation.

Effect example 1: cytotoxicity test

1. Experimental samples:

1. KND-COVID-III: the dry extract powder prepared in example 1 was used;

2. rede Siwei: purchased from MedChemexpress under the product number HY-104077;

2. the experimental process comprises the following steps:

1. sample preparation:

A. preparing KND-COVID-III samples: adding 200 mu L of infection culture medium into a No. 2-6EP tube, adding 800 mu L of KND-COVID-III (1600 mu g/mL) and 200 mu L of infection culture medium into a No. 1 EP tube, blowing and mixing uniformly, adding 200 mu L of total sample of the No. 1 tube into a No. 2 tube, blowing and mixing uniformly, adding 200 mu L of total sample of the No. 2 tube into a No. 3 blowing and mixing uniformly, and the like; finally, a turbid liquid is obtained, wherein the medicine contents are 800 mug/mL, 400 mug/mL, 200 mug/mL, 100 mug/mL, 50 mug/mL and 25 mug/mL respectively;

B. preparation of a positive drug, namely Redexivir: adding 6 mu L of Ruidexivir to 594 mu L of infection culture medium, preparing the Ruidexivir into 100 mu M solution, marking the solution as a No. 1 tube, adding 400 mu L of infection culture medium into a No. 2-6 tube, blowing and mixing uniformly, adding 200 mu L of total sample of the No. 1 tube to a No. 2 tube, blowing and mixing uniformly, adding 200 mu L of total sample of the No. 2 tube to a No. 3 blowing and mixing uniformly, and so on until Ruidexi Wei Peizhi is completed; the drug contents were 20. Mu.g/mL, 10. Mu.g/mL, 5. Mu.g/mL, 2.5. Mu.g/mL, 1.25. Mu.g/mL, and 0.625. Mu.g/mL, respectively.

2. Cell inoculation:

VeroE6 cells at 1.0X10 per well ⁴ The cells were inoculated into 96-well cell culture plates and incubated overnight at 37℃for further use. After the cells are attached overnight, the supernatant of the culture medium is removed, KND-COVID with different concentrations is addedIII and the positive drug adefovir treated cells. The cells were exposed to 5% CO at 37 ℃ ₂ After culturing in the incubator for 24, 48 and 72 hours, respectively, detection was performed. And (3) detection: 10. Mu.L of CCK-8, 37℃and 5% CO were added to each well ₂ In the incubator of (2) to culture lh. The OD value at 450nm was measured on a microplate reader for data analysis.

3. Experimental results and analysis

1. Calculating the cell survival rate based on the measurement result of the enzyme label instrument, wherein the result is shown in table 1;

2. the results of the cell viability curves at the different dosing concentrations were obtained by plotting GraphpadPrism5 on the abscissa with log (dosing concentration (. Mu.g/mL)) and cell viability (average of the two data) on the ordinate, as shown in FIGS. 1-2; and calculate CC ₅₀ (cell median lesion concentration); CC (CC) ₅₀ (cell median lesion concentration) =nonlin fit/Sigmoidal dose-response (variable slope)

TABLE 1

From the data in table 1 and fig. 1-2, one can: half-cytotoxicity concentration CC of adefovir against Omicron virus ₅₀ Half cytotoxicity concentration CC of KND-covd-III (traditional Chinese medicine formulation) against Omicron virus =0.003 μg/mL ₅₀ The above data demonstrate that KND-covd-III (chinese herbal formulation) is less cytotoxic and that cell viability increases with increasing dosing concentration, as KND-covd-III and radexivir are able to increase ACE2 immunity.

Effect example 2: anti-SARS-CoV-2 (Omicron) Activity assay (q-PCR method)

1. Experimental sample

1. KND-COVID-III: effect example 1;

2. rede Siwei: effect example 1;

3. novel coronaviruses: omicron virus strain derived from national virus resource library of the institute of Chinese academy of sciences of Wuhan virus

2. Experimental procedure

Step 1, sample preparation: effect example 1;

step 2, cell culture: ver E6 cells were plated one day in advance, 2.0X10 cells per well ⁴ The individual cells, cell plates were cultured overnight;

step 3, drug administration: 2-time gradient dilution, 6 concentrations and three compound wells are set in the experiment, a cell control well (without adding medicine and virus) and a virus control well (without adding medicine and virus) are set in the experiment, and prepared KND-COVID-III and Ruidexivir are respectively added into the cell wells, wherein each well is 100 mu L; 100uL of infection medium was added to the cell control wells and virus control wells.

Step 4, infection: diluting the virus source solution by 100 times with the infected culture medium, adding the diluted virus into the cell hole containing the medicine and the virus control hole in the step C, wherein 100 mu L of the virus source solution is added into each hole, and the MOI is about 0.01. The cell control hole is added with 100 mu L of the infected culture medium;

step 5, detecting a culture medium: placing the cell plate into CO ₂ Incubating for 24 hours at 37 ℃ in an incubator, taking 200 mu L of culture supernatant, extracting viral RNA by using an RNA extraction kit, and obtaining a CT value according to nucleic acid detection.

3. Experimental results and analysis

1. Based on the detection result of nucleic acid, the inhibition rate of antiviral drugs at different concentrations is calculated, and the calculation formula is inhibition rate= (1-2) ^-ΔCT ) X 100%; the results are shown in Table 2.

2. The inhibition ratio (average of 2 data) is plotted on graph pad Prism5, log (dose concentration (. Mu.g/mL)) on abscissa and inhibition ratio (average of 2 data) on ordinate, and inhibition ratio curve results at different dose concentrations are obtained as shown in FIGS. 3 to 4; and calculate IC ₅₀ (half-cell inhibition rate); IC (integrated circuit) ₅₀ (half cell inhibition) =nonlin fit/Sigmoidal dose-response (variable slope)

TABLE 2

From the data in Table 2 and FIGS. 3-4, it can be seen that: half-effective concentration of adefovir against Omicron virus IC ₅₀ Half cytotoxicity concentration IC of KND-covd-III (chinese herbal formulation) against Omicron virus=2.57 μg/mL ₅₀ Because of the fact that =1.02 μg/mL is 2-3 times of the radexidine, the present invention has a better effect of inhibiting novel coronaviruses, which is equivalent to the radexidine in effect, even as high as Yu Ruide.

The above described embodiments are only preferred examples of the invention and are not exhaustive of the possible implementations of the invention. Any obvious modifications thereof, which would be apparent to those skilled in the art without departing from the principles and spirit of the present invention, should be considered to be included within the scope of the appended claims.

Claims

1. The traditional Chinese medicine composition for treating the novel coronavirus infection is characterized by comprising the following raw materials in parts by weight:

2. The traditional Chinese medicine composition for treating novel coronavirus infection according to claim 1, further comprising pharmaceutically acceptable auxiliary materials.

3. A clinical formulation comprising the traditional Chinese medicine composition for treating a novel coronavirus according to any one of claims 1-2.

4. A clinical formulation according to claim 3, wherein the clinical formulation is an oral formulation; the oral preparation is selected from decoction, powder, capsule, tablet, mixture, syrup, oral paste, pill or oral liquid.

5. A method of preparing a clinical formulation according to claim 3, comprising the steps of:

step 2, adding water into the raw material powder, decocting for 2-3 times under the stirring condition of 90-100 ℃, filtering, combining the filtrates, and concentrating under reduced pressure to obtain paste;

and 3, freeze-drying the paste to obtain dry paste powder.

6. The method according to claim 5, wherein in step 2, after the filtrates are combined, the filtrate is centrifuged at a low temperature and the supernatant is dried under reduced pressure.

7. The method for preparing a clinical preparation according to claim 5, wherein the mass-to-volume ratio of the raw material powder to water is 25g in dry weight: 0.7-1.3L;

the filtering adopts a 80-120 mesh sieve;

the temperature of the reduced pressure concentration is 50-55 ℃.

8. The method for preparing a clinical preparation according to claim 5, further comprising the steps of 4, granulating:

according to the mass ratio of the dry paste powder to the starch of 1:0.5-1.5, mixing the dry paste powder with starch uniformly, adding ethanol solution, making into soft material, granulating with 16-20 mesh sieve, oven drying at 60-65deg.C, and sieving with 14-18 mesh sieve to obtain granule.

9. The method of claim 5, wherein the granule prepared in step 4 is encapsulated to obtain a capsule preparation;

or tabletting the granules prepared in the step 4 to obtain tablets.

10. Use of a traditional Chinese medicine composition according to any one of claims 1-2 or a clinical preparation according to claims 3-4 or a clinical preparation prepared by a preparation method according to claims 5-9 for the preparation of a medicament for the treatment of a novel coronavirus infection.